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SUMMARY
Hand, foot and mouth disease (HFMD) is generally a benign febrile exanthematous childhood
disease caused by human enteroviruses. The route of transmission is postulated to be faeco-oral
in developing areas but attributed more to respiratory droplet in developed areas. Transmission is
facilitated by the prolonged environmental survival of these viruses and their greater resistance to
biocides. Serious outbreaks with neurological and cardiopulmonary complications caused by
human enterovirus 71 (HEV-71) seem to be commoner in the Asian Pacific region than elsewhere
in the world. This geographical predilection is unexplained but could be related to the frequency
of intra- and inter-typic genetic recombinations of the virus, the host populations’ genetic
predisposition, environmental hygiene, and standard of healthcare. Vaccine development could
be hampered by the general mildness of the illness and rapid genetic evolution of the virus.
Antivirals are not readily available; the role of intravenous immunoglobulin in the treatment of
serious complications should be investigated. Monitoring of this disease and its epidemiology in
the densely populated Asia Pacific epicentre is important for the detection of emerging epidemics
due to enteroviruses.
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VIROLOGY
The family Picornaviridae contains 12 genera of
non-enveloped, linear positive-sense, single-stranded
RNA viruses which include Aphthovirus, Cardiovirus,
Enterovirus, Erbovirus, Hepatovirus, Kobuvirus,
Parechovirus, Teschovirus, Tremovirus, Avihepato-
virus, Senecavirus, and Sapelovirus [1]. The last five
genera have not so far been associated with human
infections to date. The currently recognized species
and types of Enterovirus are listed in Table 1 [1, 2].
In addition to the classical communicable disease
syndromes such as poliomyelitis, herpangina, hepa-
titis A, and common cold, several new picornaviruses
are found in humans. These newly described viruses
include human parechoviruses, Saffold Cardiovirus,
Klassevirus, Salivirus and other yet unclassified
viruses, but their association with clinical disease is
still unclear [3–8].
The genome of human enterovirus 71 (HEV-71)
is about 7.4 kb in size, which is flanked by 5k and 3k
untranslated regions. The protein-coding region can
be divided into three regions: P1 encodes for the
structural proteins VP4, VP2, VP3, and VP1; P2 and
P3 for the non-structural proteins 2A, 2B, 2C and
3A, 3B, 3C, 3D, respectively [9, 10]. A single, long
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polyprotein is translated from the viral RNA which
is then cleaved to form the individual proteins. VP1
carries most of the type-specific neutralizing antibody
epitopes. Mutations in VP1 have been associated with
increased virulence in animal models [11].
HEV-71 has three genotypes (A, B, and C) based
on VP1 and VP4 gene sequences. Genotypes B and C
are each further divided into five subtypes B1–B5
and C1–C5, respectively. More recently, analysis of
complete genome sequences of HEV-71 (including
non-structural protein genes) suggested that sub-
genotype C4 should be classified as a new genotype D
(Fig. 1) [12]. Retrospective analysis of strains of
HEV-71 isolated in The Netherlands from 1963 to
1967 suggested that there is a new subgenotype B0
[13].
Genetic recombination among RNA viruses was
first noted in poliovirus [14]. Recombination occurs
through template switch and other mechanisms
mainly in the non-structural protein region of the
genome [14, 15]. Intra-typic recombinations are
commoner than inter-typic ones owing to the higher
degree of sequence homology between the gene seg-
ments. Recombination is also frequent and a major
source of genetic variation in other non-polio
enteroviruses [16–20]. Most recombination occurs
within the same species of virus ; natural inter-species
recombination is uncommon. Intra-typic and inter-
typic HEV-71 recombinants have been detected in
outbreaks in the Asia Pacific region. In Malaysia,
inter-typic recombinants of HEV-71 have been de-
scribed with the P3 region being derived from CV-
A16 [21]. In China, intra-typic recombinants were
found to be circulating in the 2008 outbreak of
HEV-71 [22]. Although recombinants can be a driving
force in the genesis of new epidemics, other factors
such as cross-protection with other genotypes, viru-
lence, and transmissibility may also play a role in
determining the size and outcome of epidemics.
Examples of both intra-typic and inter-typic recom-
binations are shown in Figure 2. Bootscan analysis
of a recent EV-71 strain identified in Guangzhou
suggested that intra-typic recombination occurs be-
tween EV-71 genotypes B and C at junctions 2A–2B
and 3C; however, the analysis of a recent HEV-71
strain identified in Shanghai suggested inter-typic re-
combination between HEV-71 genotype C and CA16
G-10.
PATHOGENESIS AND PATHOLOGY
At least three human cellular receptors of HEV-71
have recently been identified [23–25]. The relative
importance of these receptors in different tissues or in
different phases of the infection awaits clarification.
Human dendritic cells are susceptible to infection by
HEV-71 through DC-SIGN [dendritic cell-specific
intracellular adhesion molecules (ICAM)-3 grab-
bing non-integrin, also known as CD209] [23]. In-
fected dendritic cells serve as antigen-presenting
cells with the ability to prime T cells to generate
protective immune responses. DC-SIGN is unlikely
to be the sole receptor for HEV-71 since cell types
not expressing DC-SIGN can also be infected by the
virus.
Another HEV-71 cellular receptor is the human
P-selectin glycoprotein ligand-1 (CD162) [24]. CD162
is a cell surface glycoprotein which plays an important
role in the binding of leukocytes to endothelial cells
and platelets. It is expressed on the surface of cells
of haematopoietic origin but not on parenchymal
cells of most tissues. Cells expressing the ligand in-
clude circulating leukocytes, dendritic cells, tissue
macrophages (such as those in liver, lung, bowel, and
Langerhans cells in the skin) and myeloid progenitor
cells [26]. Its presence on the macrophages in the
Table 1. Enteroviral species and types currently
recognized
Enterovirus species Types
Human enterovirus A Human Coxsackievirus
A2–8, 10, 12, 14, 16.
Human enterovirus 71,
76, 89–92.
Human enterovirus B Human Coxsackievirus A9,
B1–6.
Human echovirus 1–9,
11–21, 24–27, 29–33.
Human enterovirus 69,
73–75, 77–88, 93, 97, 98,
101, 106, 107.
Human enterovirus C Human poliovirus 1–3.
Human Coxsackievirus A1,
11, 13, 15, 17–22, 24.
Human enterovirus 95, 96,
99, 102, 104, 105, 109.
Human enterovirus D Human enterovirus 68,
70, 94.
Human rhinovirus A, B, C
Porcine enterovirus B
Bovine enterovirus
Simian enterovirus A
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mucosa-associated lymphoid tissues of the alimentary
tract has been postulated to represent the primary site
of viral multiplication after infection and the infection
and activation of Langerhans cells in the skin reflects
the genesis of the skin lesions typical of hand, foot
and mouth disease (HFMD) [24].
A third receptor is the scavenger receptor BII
(SR-BII) which has the physiological function of
mediating high-density lipoprotein uptake into and
cholesterol efflux from cells [25, 27, 28]. It is expressed
in significant amount in various organs and cells,
including the liver, spleen, testes, retinal pigment epi-
thelial cells, osteoblasts, macrophages, and import-
antly, the brain [29–31]. The scavenger receptor class
B is also involved in the uptake of the hepatitis C
viruses [32, 33].
The ubiquity of HEV-71 receptors in different
organs may account for the systemic nature of
HEV-71 infection in severe cases and the predilection
for involvement of the central nervous system (CNS).
In poliovirus infection, the poliovirus receptor CD155
is present in a large number of organs and tissues,
yet not all these organs are sites of viral replication
or exhibit the pathology of infection [34, 35]. Hence,
the presence of receptors per se may be a necessary
but not sufficient prerequisite for the pathogenesis
of the infection. Both polioviruses and HEV-71 are
neurotropic, thus explaining their propensity to
cause neurological complications such as acute flaccid
paralysis. Neuropathological examination of fatal
human encephalomyelitis patients showed that in-
flammation involved the whole grey matter of the
spinal cord, tegmentum of the midbrain, hypothala-
mus, and subthalamic and dentate nuclei, and more
focally and less intensely in the cerebral cortex,
especially the motor cortex. The virus may enter
the CNS via the motor pathway of the peripheral
nervous system, possibly through retrograde axonal
transport [36, 37]. This is supported by the in vitro
finding that infection of the human neuronal cell line
(SK-N-SH) by HEV-71 resulted in the highest level of
viral replication when compared to human laryngeal
(HEp-2), human glial (U373MG), and African green
monkey kidney (Vero) cell lines [38]. Experimental
evidence suggested that HEV-71-infected cells (in-
cluding neurons and Vero cells) undergo apoptosis
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Fig. 1. Phylogenetic analysis of all genotypes of EV-71 represented by their most recent isolates based on alignment of VP1
gene sequence available in GenBank (891 nucleotide positions in each VP1 region were included in the analysis). The scale
bar indicates the estimated number of substitutions per 100 bases. Phylogenetic tree construction was performed using
neighbour-joining method with GrowTree using Kimura’s two-parameter correction, with bootstrap values calculated from
1000 trees (Genetics Computer Group Inc., USA)
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through a variety of pathways [39–43]. In addition,
neuronal damage can also be caused by HEV-71-
induced cellular autophagy [44]. Finally, HEV-71
infection of endothelial cells can lead to activation
and apoptosis ; this may serve as an alternative
mechanism of end organ damage in systemic infec-
tions [43].
The brains of patients who developed HEV-71
encephalitis generally showed oedema, vascular
congestion, and typical pathological features of
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Fig. 2. (a) A recent example of intra-typic recombination reviewed by bootscan analysis [bootscanning was conducted with
Simplot version 3.5.1 (Kimura distance model: window size 500 bp, step 20 bp) on a gapless nucleotide alignment, generated
with ClustalX, with the genome sequence of the EV-71 strain (01/Guangzhou/China/2008) as the query sequence]. (b) A
recent example of inter-typic recombination reviewed by bootscan analysis [bootscanning was conducted with Simplot
version 3.5.1 (Kimura distance model: window size 500 bp, step 20 bp) on a gapless nucleotide alignment, generated with
ClustalX, with the genome sequence of the EV-71 strain (036/Shanghai/China/2009) as the query sequence].
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encephalitis [45–47]. There is a predominant involve-
ment of the grey matter especially in the brainstem;
inflammation in cerebellum, spinal cord, and the men-
inges is often present. Involvement of the cerebrum
is generally less intense. Neuronal degeneration and
necrosis are common. The inflammatory response is
characterized by perivascular mononuclear cell infil-
tration. Micro-abscess formation and glial nodules
may also be seen. The lung of a patient with cardio-
pulmonary failure is characterized pathologically by
oedema, diffuse alveolar damage and the presence
of inflammatory infiltrates [45]. Viral myocarditis is
not a feature of HEV-71-associated cardiopulmonary
failure in patients who developed brainstem encepha-
litis. The myocardium showed coagulative myocy-
tolysis and myofibrillar degeneration, which suggested
that the pathogenesis is one of neurogenic cardiac
damage rather than direct involvement by infection
[48, 49].
PROTECTIVE IMMUNITY
There is clinical and experimental evidence on the
roles of different arms of immune responses in
the protective immunity against HEV-71 infection.
The cellular and humoral immune responses are both
essential for decreasing the viral load and mortality in
mice [50]. In humans, cellular immunity is important
in preventing the development of serious compli-
cations after HEV-71 infection [51, 52]. On the other
hand, the neutralizing antibodies from the humoral
response appear to be crucial in the protective im-
munity against infection [53–55]. During the 1998
epidemic in Taiwan, attack and case-fatality rates
were lowest in seropositive infants aged <6 months,
suggesting a protective role of maternal antibodies
[56, 57]. In humans, presence of maternal anti-
HEV-71 antibodies has also been demonstrated in
neonates, the prevalence and titre of which correlate
with those levels in the mothers [58]. In mice, trans-
plancental transfer of antibodies following maternal
immunization against EV-71 protects against lethal
infection of newborn mice [59]. Thus, it appears that
the seroprevalence of neutralizing antibodies inwomen
of childbearing age is important in protecting infants
aged<6 months. The protective role of breastfeeding
also needs to be studied: breast milk contains lacto-
ferrin which inhibits binding of HEV-71 to host cells.
Whether secretory IgA in maternal milk contributes
to the mucosal immunity against HEV-71 (as has been
proven in the case of poliovirus) is not known.
CLINICAL DISEASE
Many picornaviral infections occur mainly in child-
hood. The propensity to cause outbreaks is an
important feature of some of these viruses, most
notably poliomyelitis in the pre-vaccination era
and now, enteroviruses. Enterovirus outbreaks range
from small community clusters of acute haemorrhagic
conjunctivitis due to Coxsackieviruses to large nation-
wide HEV-71 epidemics. Most enteroviral infections
are asymptomatic which adds to the difficulty in con-
trolling spread in the community.
Clinical syndromes typically associated with entero-
viral infections include undifferentiated fever ; neuro-
logical manifestations (acute flaccid paralysis, aseptic
meningitis, meningoencephalitis) ; respiratory infec-
tions with exanthems and/or enathems (HFMD,
herpangina) ; eye infections (acute haemorrhagic con-
junctivitis) ; cardiovascular infections (pericarditis,
myocarditis) ; muscle diseases (pleurodynia and Born-
holm disease) ; and systemic infections.
HFMD is a common illness in children aged
<10 years. The infection typically has an incubation
period of 3–7 days. The main manifestations are fever,
lymphadenopathy, followed in 1–2 days’ time by the
appearance of vesicles on the palmar and plantar skin,
buccal mucosa, and tongue. Papular and vesicular
lesions can also occur on other parts of the body. The
oral enanthem helps to distinguish HFMD from
other causes of childhood exanthems, although cases
without oral lesions have been described. Uncom-
plicated HFMD usually resolves in 5–7 days. CV-A16
and HEV-71 are the commonest causes of HFMD,
the latter is especially common in the Asia Pacific
region. Other enteroviruses causing HFMD include
CV-A4 to A7, A9, A10, A24, B2–B5, echoviruses 1, 4,
11, 18, and HEV-18. Clinical features of HFMD
caused by these viruses are indistinguishable. In con-
trast to CV-A16, HFMD caused by HEV-71 is more
likely to cause a high fever (o39 xC) and fever for
>3 days, more severe illness, and a higher risk of
developing complications and fatalities [60, 61].
HFMD is rare in adults but cases due to HEV-71
have been reported. Adults can also develop severe
HEV-71 infections such as encephalitis as a result of
intra-familial transmission [62, 63].
HEV-71 infection commonly manifests as HFMD
or herpangina. In a few patients, neurological and
cardiopulmonary complications with substantial mor-
tality may occur. No specific genotype is associated
with more severe disease [64]. Children aged<5 years
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have the highest incidence of severe complications
[65–67]. Fatal cases of HFMD due to HEV-71 were
more often associated with vomiting and a lower
incidence of mouth ulcers [61]. The predominant
forms of neurological syndrome include aseptic men-
ingitis, acute flaccid paralysis, brainstem encephalitis,
or cerebellitis and vary in different epidemics. These
complications often appear early, at 2–5 days after
the onset of illness [68]. Over an 8-year period from
1998 to 2005, the case-fatality rate of complicated
enteroviral infections – most of which were caused by
HEV-71 – ranged from 10.0% to 25.7% [65].
Long-term neurological sequelae are common in
survivors who had more serious CNS disease and
cardiopulmonary failure. Late complications include
limb weakness, dysphagia requiring tube-feeding,
cerebellar dysfunction, delayed neurodevelopment,
and impaired cognitive functions [69, 70].
Acute cardiopulmonary failure as a complication
of systemic HEV-71 infection has a high mortality.
Pulmonary oedema is related to cerebral compression
or increased intracranial pressure which leads to sym-
pathetic hyperactivity [71]. Pulmonary oedema and
the associated hypoxaemia and acute respiratory dis-
tress syndrome are the commonest causes of death
in severe HEV-71 infections. Similarly, brainstem
encephalitis leads to acute heart failure in 19% of
patients and this complication has a high mortality
rate of 77% [48]. Again, hyperactivity of sympathetic
stimulation to the heart leading to a ‘catecholamine
storm’ and neurogenic cardiac damage is believed to
be the mechanism of cardiac damage in this infection.
Risk factors associated with the progression to
CNS involvement without pulmonary oedema in
HEV-71 infection included fever for o3 days, peak
body temperature of o39 xC, the presence of
headache, lethargy, vomiting, seizure, and hyper-
glycaemia. Hyperglycaemia, leucocytosis, and limb
weakness were found to be risk factors for pulmonary
oedema [72]. In some series, a higher level of leuco-
cytosis was found in patients with CNS involvement
[73]. In a series of 333 patients with CNS involvement
due to non-poliovirus in Taiwan, severe CNS disease
was associated with age <4 years, leucocytosis (over
13r109/l), seizure, myoclonic jerks, and a higher
incidence of skin rash and oral ulcers [74].
In those patients who developed serious CNS dis-
ease due to non-poliovirus infection, poor prognostic
factors included age <2 years, higher peak leucocyte
counts (over 17r109/l), a higher incidence of skin
rash, and a lower yield of virus from the cerebrospinal
fluid [74]. For HEV-71 cardiopulmonary failure,
poorer clinical outcomes were associated with higher
troponin I level, lower initial systolic blood pressure,
longer duration of hypotension, greater requirements
for inotropic support, lower PaO2 :FiO2 ratio, higher
white blood cell counts in the cerebrospinal fluid, and
the lowest Glasgow coma score. Fatality correlated
best with the troponin I level [75].
LABORATORY DIAGNOSIS
Aetiological diagnosis of HFMD can be achieved
by examining the vesicular fluid aspirated from the
skin lesion and naso-/oro-pharyngeal swabs. In com-
plicated cases with brainstem encephalitis and cardio-
pulmonary failure with sparse skin lesions HEV-71
may still be detectable in the cerebrospinal fluid,
naso-/oro-pharyngeal secretions, or faeces. The com-
monest rapid diagnostic test is by reverse tran-
scription–polymerase chain reaction (RT–PCR) of
the RNA extracted from these specimens, targeting
towards the 5k untranslated or VP1 region of the
viral genome [76–78]. Isolation of virus from clinical
specimens is possible using conventional cell culture
or rapid shell viral culture with rhabdomyosarcoma
(RD), HEp-2, colonic carcinoma (CaCo-2), or Vero
cell lines and cytopathic effects can be seen in 3–7 days
[79]. Cell lines infected by HEV-71 or CV-A16 can
be differentiated by immunostaining with specific
monoclonal antibodies against their VP1 proteins.
The isolates can be genotyped by PCR sequencing
of the VP1 and/or VP4 genes. IgM antibody to
HEV-71 has been detected as early as 2 days after
onset of illness but, as the test is not yet widely avail-
able, serological diagnosis generally requires demon-
stration of a fourfold rise in neutralizing antibody
titre taken 10–14 days after the onset of illness [80].
EPIDEMIOLOGY
HEV-71 was first detected in 1969 in California in
an infant suffering from encephalitis. Initial isolations
of HEV-71 were made in the USA and in Australia
in the early 1970s, and outbreaks of HFMD occurred
in Sweden and Japan [81, 82]. In the late 1970s,
Bulgaria (1975) and Hungary (1978) witnessed large
epidemics of HEV-71 infection with prominent neuro-
logical manifestations (aseptic meningitis, encepha-
litis, acute flaccid paralysis) [83, 84]. Since the late
1990s the densely populated Asia Pacific region has
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been the hotspot for epidemics: Taiwan, Singapore,
Malaysia, China, Vietnam, and Australia have ex-
perienced recurrent epidemics of various sizes. The
reason for this geographical distribution is uncertain,
but the association between HLA-A33 (which is
common in some Asian populations) and suscepti-
bility to HEV-71 infection has been suggested as a
possible explanation [85]. Other factors such as gen-
etic predisposition (glucose-6-phosphate dehydro-
genase deficiency, polymorphisms in cytotoxic T
lymphocyte antigen-4 and scavenger receptor BII),
food and water hygiene, and micronutrient de-
ficiencies require further studies to confirm their sig-
nificance [51, 86–91].
Recent epidemics of HFMD disease in the Asia
Pacific region were mainly caused by HEV-71
(Table 2). However, more than one subgenotype of
HEV-71 can be found co-circulating in the same epi-
demic, as well as other non-HEV-71 enteroviruses,
such as CV-A16 (Table 3). Co-infection is possible in
enteroviral HFMD [92, 93]. In Sarawak, Malaysia,
co-infection of HEV-71 with other viruses occurred
in 10% of patients [93]. Co-infection does not appear
to result in more severe clinical disease [92].
The Taiwan epidemic of HEV-71 HFMD in 1998
was the largest outbreak in the Asia Pacific region
until 2008, when 488955 cases of HFMD were re-
ported in China (Table 2), certainly an underesti-
mation of the actual burden of disease. More than
600000 cases were reported fromMarch to June 2009,
but this could be because HFMD became a notifiable
disease in China from May 2008. The epidemic centre
in China in 2008 was the southeastern provinces of
Guangdong, Zhejiang, and Anhui. The overall case-
fatality rate reported from China in 2008 and 2009
was about 0.03%, but in certain local outbreaks,
such as the 2008 outbreak in Fuyang City of Anhui
Province, the case-fatality rate was as high as
0.3% [94].
Humans are the only known natural hosts of
HEV-71. Intra-familial transmission of HEV-71 oc-
curs commonly. In a prospective cohort in Taiwan,
transmission rates from infected children to siblings
were as high as 84% [66]. The rate of symptomatic
infection after household transmission is higher than
that in other community settings (94% vs. 29%)
which is attributed to more prolonged contact with
the cases and possibly a larger infective dose. Faeces
and oropharyngeal secretions are likely to be import-
ant in the transmission of the virus. Shedding of
non-polio enteroviruses in the stool can persist for
3–11 weeks after the onset of illness, while the dur-
ation of shedding from oral secretion is shorter [95,
96]. Enteroviruses are also detectable in throat swabs.
During the 1998 Taiwan HEV-71 epidemic, detection
of the virus from the throat swabs was more frequent
than from stool specimens; the time to positivity
by viral culture was also shorter [97]. The superior
recovery rate of enteroviruses, mainly HEV-71 and
CV-A16, from throat swabs over stool samples (with
or without the testing of vesicle swabs) in HFMD was
confirmed in another study in Sarawak, Malaysia [98].
A recent study from Mongolia showed that hand
washing after defecation was associated with a lower
risk of infection by non-polioviruses in households,
whilst having a bathroom in the house was a risk
factor for infection [99]. These findings suggested that
the faeco-oral route is probably important. However,
other hygiene measures did not affect the incidence
of virus isolation. Hence, modes of transmission other
than faeco-oral could also play an important role in
the households. The relative importance or infectivity
of oropharyngeal secretions vs. faeces in real-life
situations have not been determined. We postulate
that in developing countries, sanitation plays a more
important role. In developed countries, although
personal hygiene and sanitation facilities are much
better, there is also a much larger number of facilities
where great numbers of susceptible children congre-
gate. Under such circumstances, respiratory trans-
mission may become more significant. Faeco-oral
transmission may contribute more to an endemic
disease in the community, whereas the respiratory
tract, whose secretions contain a higher viral load but
have a shorter duration of shedding than faeces, may
contribute more to the epidemic spread of the viruses
during outbreak situations. In the 1998 Taiwan epi-
demic, in addition to intrafamilial contact with cases,
attendance at a kindergarten or childcare centre and
residence in a rural area were significant risk factors
associated with HEV-71 infection. This suggests
that close contacts at schools are important in the
epidemiology of the disease by acting as sources of
spread to the community [56]. Contact transmission
from blister fluid may have a minor role.
Enteroviraemia has been demonstrated in healthy
Scottish blood donors at a predicted prevalence
of 0.023% [100]. The viruses being detected were
primarily Coxsackieviruses and human echoviruses.
Similarly, enterovirus, as well as cytomegalovirus,
parvovirus B9, and adenovirus genomes have been
detected in explanted heart myocardial tissues from
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Table 2. Recent outbreaks of HFMD due to HEV-71 in the Asia Pacific region
Year Location
Reported/
confirmed
cases Deaths Major complications
Genotype
of HEV-71
and other
co-circulating
viruses References
1997 Peninsular
and Sarawak
Malaysia
n.a. o35 Encephalomyelitis,
cardiopulmonary failure
EV-71 B3, B4
(C1, C2)
[43, 170–172]
(CV-A16, A2, A4,
A6, A9; CV-B5;
EV-1, EV-4, EV-5,
EV-7)
1998 Taiwan 129 106* 78 Aseptic meningitis.
encephalitis,
meningoencephalitis,
acute flaccid paralysis,
acute pulmonary oedema/
haemorrhage (o405 cases)
EV-71 C2 [57, 173, 174]
(CV-A16; CV-B1,
B2, B3, B5; EV-6, 7,
11, 22, 27)
1999 Australia 6000 n.a. Aseptic meningitis,
Guillain–Barre´ syndrome,
acute transverse myelitis,
acute cerebellar ataxia,
opso-myoclonus syndrome,
benign intracranial
hypertension, febrile
convulsion
EV-71 C2 [175, 176]
2000 Australia 200 n.a. Acute pulmonary oedema EV-71 B4 [175]
2000 Singapore 3790 4 (+1
possible
case)
Acute pulmonary oedema
and haemorrhage,
encephalitis, aseptic
meningitis
EV-71 B4 [82]
(CV-A16, A3, A4,
A5, A6, A10, A23;
HEV-18)
2000 Taiwan 80 677 41 291 cases EV-71 B4 [123, 174]
(CV-A16, A9, A24;
CV-B1, B3, B4;
EV-4, EV-9)
2001 Taiwan n.a. 58 389 cases EV-71 B4 [65, 174]
(CV-A16, A6, A9,
A24; CV-B4, B5;
EV-4, EV-6)
2000 Sarawak,
Malaysia
n.a. n.a. EV-71 B4 [124]
(CV-A16)
2000 Peninsular
Malaysia
n.a. n.a. EV-71 C1, B4 [170, 171]
2003 Sarawak,
Malaysia
n.a. n.a. EV-71 B4, B5, C1 [170, 171]
(CV-A16)
2005 Peninsular
Malaysia
n.a. n.a. EV-71 B5, C1 [171]
2006 Singapore 15 282 n.a. 1.8% cases hospitalized# EV-71 B5, CV-A16 [120]
2006 Brunei 1681 3 Neurological EV-71 B5 [177]
2007 China 83 344 17 [178]
2008 China 488 955 126 EV-71 C4 [178, 179]
2009 China 614 901
(March to
June 2009)
200 EV-71 C4 [22, 180]
n.a., Not available ; CV-A, Coxsackievirus A; HEV, human enterovirus; EV, echovirus. Viruses or genotypes in parentheses are not
the predominant strains.
* Actual number of cases estimated to be ten times higher.
# Compared to 0.7–0.8% in epidemics due to CV-A16.
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Table 3. Summary of predominant EV-71 genotypes in the Asia Pacific region
Year B1 B2 B3
Genotypes
B4 B5 C1 C2 C3 C4 C5
1986 Sydney
1987 Sydney
1989 Sydney
1990 Sydney
1991 Sydney
1993 Japan
1994 Sydney
1995 Sydney Australia
1996 Sydney
1997 Sarawak Malaysia,
peninsular Malaysia,
Singapore, Japan
Peninsular Malaysia,
Singapore, Japan
Peninsular Malaysia Peninsular Malaysia,
Japan
China
1998 Sarawak Malaysia,
Singapore
Peninsular Malaysia,
Taiwan
Sarawak Malaysia,
peninsular Malaysia,
Singapore
Peninsular Malaysia,
Taiwan
China
1999 Sarawak Malaysia,
Singapore, Perth
Peninsular Malaysia,
Taiwan
Peninsular Malaysia Peninsular Malaysia,
Perth
China
2000 Sydney, Sarawak
Malaysia, peninsular
Malaysia, Taiwan,
Singapore
Peninsular Malaysia,
Japan
Sarawak Malaysia,
peninsular Malaysia,
Perth
Peninsular Malaysia Korea China
2001 Sarawak Malaysia,
Sydney, Taiwan,
Singapore
China
2002 Sarawak Malaysia,
Taiwan, Singapore
Sarawak Malaysia,
Singapore, Thailand
China
2003 Taiwan SarawakMalaysia Sarawak Malaysia China, Japan
2004 China, Taiwan
2005 Peninsular Malaysia Peninsular Malaysia,
Vietnam
Taiwan, Vietnam Vietnam
2006 Singapore, Brunei,
Taiwan
Taiwan
2007 Taiwan China Taiwan
2008 China
2009 China
Boldface indicates major outbreaks as indicated by the reports showing a significant increase in incidence above their local baseline.
Data from references [22, 64, 124, 171, 175, 179, 181–186].
H
u
m
a
n
en
tero
v
iru
s
7
1
a
n
d
H
F
M
D
1
0
7
9
heart transplant donors and recipients in Germany.
The prevalence of enterovirus as detected by RT–
PCR reaction ranged from 21% to 60% of the heart
samples [101]. During the HEV-71 epidemic in
Taiwan in 1998, 20% of patients in one study had
viraemia as detected by RT–PCR [73]. Although these
findings suggested that transfusion of blood products
and transplantation could be potential routes of
transmission, such cases have not yet been reported.
One case of intrauterine infection by HEV-71 was
reported and the pregnancy was complicated by still-
birth with virological evidence of brain and liver
involvement [102]. Another baby who developed
perinatal HEV-71 infection with HFMD and aseptic
meningitis had a benign course and recovered without
long-term neurological sequelae [103].
The contribution of environmental factors in the
ecology and transmission of HEV-71 is not well
understood. Few environmental studies specifically
addressed HEV-71, although one may draw infer-
ences from studies involving other better studied
picornaviruses such as poliovirus and Coxsackie-
viruses. Enteroviruses have a higher level of resistance
to biocides compared to other enveloped viruses.
They are fairly tolerant to temperature, salinity, pH,
and sewage treatment procedures. Different types
of enteroviruses – including HEV-71 – can readily be
detected in sewage and other environmental waters
[104, 105]. The finding of enteroviruses in surface
waters has no correlation with the level of other indi-
cator organisms of water pollution. Outbreaks of
picornavirus meningitis have occurred with the
sources traced to potable or recreational water
sources. Examples include swimming pools (echovirus
30 aseptic meningitis), campsite swimming pool (echo-
virus 9 aseptic meningitis), nature-like swimming
pond (echoviruses 30 and 13), tap and bottled drink-
ing water (echoviruses 30 and 6, CV-B5) [106–109].
Inadequate chlorination might have accounted for
some outbreaks; however, the usual levels of chlori-
nation in swimming pools and potable water
(2–4 ppm and 1 ppm free chlorine, respectively) do
not reliably inactivate picornaviruses. Viable entero-
viruses can also be isolated from bottled and tap
water (vaccine strain of poliovirus, Coxsackievirus B,
echoviruses) [110–112]. The waterborne outbreak in
Belarus in 2003, mainly caused by Echovirus 30 and
to a lesser extent, Echovirus 6, was one of the largest
outbreaks, affecting 1222 children; 57.5% of the
patients developed meningitis [109]. Interestingly,
during the 1998 Taiwan outbreak, usage of tap water
was found to be a risk factor for acquisition of
HFMD or herpangina in univariate analysis [56].
However, the study did not specify whether the
contact involved drinking unboiled tap water, rinsing
of mouth during tooth brushing or face washing.
The role of cross-infection caused by backwashing
of infected saliva onto drinking fountains used in
schools and other public facilities has not been in-
vestigated.
In addition to drinking water, sewage contami-
nation of coastal and marine waters can also lead
to accumulation of enteroviruses in molluscs. Clams,
mussels, oysters, and crabs have been found to have
a high prevalence of enteroviruses (ranging from
8% to 40% in some studies), frequently in the pres-
ence of a normal coliform count in the samples
[112–116]. Foodborne transmission of HEV-71 in
humans has not been demonstrated. However, it
would not be surprising if this turns out to be an im-
portant route of transmission in settings where raw
shellfish is frequently consumed. Apart from hepatitis
A virus, another picornavirus, Aichi virus, has been
found to be involved in causing outbreaks of gastro-
enteritis related to consumption of oysters and other
seafood in France, and the seroprevalence among
adults in the general populations was up to 85%
[117–119].
Although the role of environmental viruses in the
transmission and maintenance of HEV-71 infection
remains to be defined, their contribution needs to be
further studied, especially in developing countries
where sewage treatment, quality of potable water
supply, and food hygiene could be suboptimal. Never-
theless, these environmental factors will not be the
sole determinants of the epidemiology of HEV-71
infections. Some developing countries such as India
has not reported major outbreaks, whereas high
prevalence of enteroviruses has been found in potable
water in developed countries like Korea, and epi-
demics of HEV-71 HFMD have occurred in devel-
oped countries such as Singapore and Taiwan [120].
The policy of surveillance for HFMD and HEV-71
and class suspension in cases of school outbreaks
may have helped to limit the size of outbreaks in sev-
eral of the endemic Southeast Asian countries [121,
122]. Various control measures at epidemic sites
such as school closure or discontinuation of drinking
fountains have not been adequately evaluated. Such
measuresmay theoretically reduce interpersonal trans-
mission at these sites and so prevent further com-
munity spread of the virus.
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The peak season for HFMD and HEV-71 infec-
tion is generally the summer months. Epidemics of
HEV-71 infection tend to occur once every 2–5 years.
The cyclical appearance of epidemics could be due
to the accumulation of susceptible individuals in
the community. On the other hand, introduction of
new genotypes or emergence of new genotypes or
strains has led to outbreaks in the Asia Pacific region
[64]. Studies in Taiwan showed that the level of sero-
prevalence against HEV-71 in different parts of the
island and the age-specific seroprevalence are corre-
lated with the incidence of severe disease and mor-
tality rates [56]. Emergence of a new genotype or
subgenotype of HEV-71 could contribute to the oc-
currence of outbreaks. The two changes in the pre-
vailing genotype of HEV-71 in Taiwan can be seen in
Table 3, with the epidemics in 1998 and 2000 being
caused by C2 and B4 strains, respectively [123].
Similarly, surveillance studies in Sarawak also dem-
onstrated the emergence of a new subgenotype C1
in the 2003 epidemic [124]. New variants of the virus
can also be generated from intra-typic and inter-typic
recombinations of the pre-existing viruses (Fig. 2)
[22, 125, 126]. Nevertheless, epidemic genotypes or
subgenotypes of the virus could circulate for a long
time before causing outbreaks. Similarly, the intro-
duction of new genotypes into a susceptible popu-
lation does not always result in large epidemics. The
lack of herd immunity towards the prevailing strains
of HEV-71 is apparently not sufficient to generate an
epidemic. Virulence of the viral strains could also be
pivotal. However, this area has not been fully studied.
A comparison of the HEV-71 strains from fatal and
non-fatal cases in Taiwan showed that they have a
very high degree of genomic identity, with only minor
differences in the homology of the 3C protease [127].
The 3C protease induces apoptosis in human neural
cells in vitro, but its role in determining the virulence
of the virus has not been documented [128]. Neither
has the role of temperature-sensitivity of the virus
been shown to be of significance in determining viru-
lence in an animal model [129]. The contribution
of micronutrient deficiencies (such as selenium and
vitamin E) in determining the outcome of HEV-71
infection is uncertain.
TREATMENT, PREVENTION, AND
CONTROL
Most HFMD cases are self-limiting and only re-
quired supportive treatment. The case-fatality rate for
HFMD of all causes ranges from 0.06% to 0.11%
[61]. The rapid progression to neurological and
cardiopulmonary complications after the onset of
HEV-71-associated disease (usually within 3–5 days)
suggests that viral replication and direct cytopathic
effects of the virus on the host cells are important
in the pathogenesis of severe manifestations [45, 67,
130]. Thus, early administration of an effective anti-
viral agent should theoretically be beneficial. There
is currently no specific antiviral approved for
HEV-71 infections. Of the available antivirals, pleco-
naril is the best studied agent against picorna-
viruses. It binds to the hydrophobic pocket in the
viral capsid VP1, thereby inhibiting the attachment,
entry, and uncoating of the virus [131]. Pleconaril
is readily absorbed after oral administration and
penetrates well into body fluids including the cer-
ebrospinal fluid. However, the drug is not readily
available in most countries and there are limited
data showing that it lacks in vitro activity against
HEV-71 [132, 133]. Pleconaril has been used in a small
number of patients suffering form HEV-71 encepha-
litis and pulmonary oedema but its efficacy cannot
be ascertained to date [133, 134]. In one study, riba-
virin showed antiviral activity against HEV-71 in vitro
and in animal models but there are no reports of its
use for treating human EV-71 infections [135]. One
animal experiment suggested that type I interferons
may have a useful therapeutic role in EV-71 infection
[136].
Agammaglobulinaemic individuals are prone to
the development of chronic enteroviral meningoen-
cephalitis. Prophylaxis and treatmentwith intravenous
immunoglobulin (IVIG) has been successful in this
group of patients and there are anecdotal reports of
successful treatment of enteroviral meningoencepha-
litis in other immuncompromised patients [137–139].
Since maternal antibody appears to be protective
against enteroviruses including HEV-71, transfusion
of maternal plasma had been used in a case of neo-
natal disseminated echovirus infection [140]. IVIG
has also been used in patients with complicated
HEV-71 infections; in addition to the presence of
neutralizing antibodies and hence the suppression
of viral replication, immunoglobulin may also play
a role in limiting organ damage through its anti-
inflammatory activities [133, 141–143]. However,
its benefits have not yet been demonstrated in ran-
domized controlled trials. Different preparations of
IVIG also vary in their titres of antibodies against
enteroviruses [144]. Based on the deleterious effects
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of dexamethasone in animals, control of the inflam-
matory response using systemic corticosteroids can-
not be recommended at present [136]. The use of
milrinone – a bipyridine inotropic agent used in the
treatment of heart failure – has been recommended
based on a historically controlled study in Taiwan
which demonstrated clinical and survival benefits in
milrinone-treated patients with pulmonary oedema
due to severe HEV-71 infection [145, 146].
With the observation that neutralizing antibodies
offer protection against infection and mortality in
humans and animal models, vaccination is an obvious
pathway towards prevention of HEV-71 infection
and epidemics. Initial work on various models of
HEV-71 vaccines (using VP1 subunits, inactivated
viruses, DNA vaccines, virus-like particles, or oral
vaccination with VP1 protein) in animals appears
promising, although still in the early stages of devel-
opment [147–151]. Animal studies with attenuated
EV-71 vaccine and human seroepidemiological studies
suggested there may be cross-protecting neutralizing
antibodies between different EV-71 genotypes [152,
153]. However, the relevance of these findings to the
development of vaccines (in terms of the choice of
and the need periodically to change vaccine strains)
is uncertain. Rapid changes in VP1 as a result of
recombination necessitate a robust surveillance of
circulating viruses. The generally mild disease mani-
festations, prevalence and lack of monitoring in some
developing countries means the incentive for vaccine
development could be low. A novel potential means
of preventing HEV-71 infection is the use of oral
lactoferrin. In vitro, lactoferrin inhibits binding of
EV-71 to cells and neonatal mice fed with recom-
binant porcine lactoferrin were protected against
lethal infection by EV-71 [154–156].
In the absence of vaccine, prevention of human
EV-71 infections still relies on basic infection control
measures, especially in schools and childcare centres.
Monitoring for the incidence of HEV-71-associated
diseases such as HFMD and herpangina is essential,
as well as virological studies to detect emergence of
new genotypes of the virus.
Proper environmental disinfection in school and
childcare centres and avoidance of possible public
sources of viral acquisition may be necessary [104,
106, 108, 157, 158]. Only one study specifically exam-
ined the efficacy of a peroxygen disinfectant on
HEV-71 [159]. In general, effective environmental
disinfectants against picornaviruses include sodium
hypochlorite, glutaraldehyde, chlorine dioxide, and
peroxygen compounds [159–162]. As an antiseptic,
povidone iodine is highly effective against non-
enveloped viruses [163]. Alcohol hand rubs commonly
used in healthcare settings contain 60–70% v/v
alcohols (such as ethanol, isopropanol, and n-
propanol). These preparations are less effective in
inactivating non-enveloped viruses than bacteria and
enveloped viruses. Higher concentrations of alcohol
(such as 85–95% v/v ethanol) are required for reliable
virucidal activities against non-enveloped viruses
[164]. Alternative hand disinfectants that can be con-
sidered include 0.2% peracetic acid with 80% (v/v)
ethanol and other newer combination alcohol-based
formulations [165–167]. These products should be
used in situations where active outbreaks of en-
terovirus infection are ongoing.
Countries in the Asia Pacific region in particular
should develop national plans for future epidemics of
HEV-71 infection. In Hong Kong, for example, the
following strategies have been developed in antici-
pation of possible community outbreaks: surveillance
and laboratory support ; clinical management and
infection control in healthcare settings ; emergency
preparedness (including stepping up of surveillance
and case investigation, mobilization of clinical and
intensive-care facilities, enhanced laboratory support,
data management, outbreak control measures, and
risk communication) ; health education and capacity
building; and applied research [168].
CONCLUSION
In the past decade, HFMD due to HEV-71 has be-
come a major public health concern in the Asia Pacific
region, which appeared to be the epicentre for the
generation of epidemic genotypes (as with influenza).
Control and prevention of the disease is a difficult
task because of the stability of the virus in the
environment and its high transmissibility, frequency
of genetic recombinations, the lack of an effective
antiviral and vaccine, and the relatively low priority
for vaccine development. Development and studies in
the only available anti-picornavirus agent pleconaril
have been minimal towards HEV-71, and newer
technologies for screening antiviral compounds, for
example, using chemical genetics and screening of
chemical libraries, may help in the discovery of a
novel agent for treatment [169]. The contributions of
genetic, environmental, and viral factors in the genesis
of epidemics in different regions of the world need
to be clarified in order to understand the varying
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epidemiology of the disease in different countries.
Similarly, the role of public health measures to reduce
the impact of outbreaks, such as school closure,
warrant further studies.
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